Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.25981 http://scihub22266oqcxt.onion/10.1002/jmv.25981 32374427!7267303!32374427     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2020 ; 92 (10): 2081-2086 Nephropedia Template TP {{tp|p=32374427|t=2020. Expression of the COVID-19 receptor ACE2 in the human conjunctiva |pdf=|usr=}}{{32374427}} gab.com Text Expression of the COVID-19 receptor ACE2 in the human conjunctiva JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32374427 #FOAvip SARS-CoV-2 is assumed to use angiotensin-converting enzyme 2 (ACE2) and other auxiliary proteins for cell entry. Recent studies have described conjunctival congestion in 0.8% of patients with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and there has been speculation that SARS-CoV-2 can be transmitted through the conjunctiva. However, it is currently unclear whether conjunctival epithelial cells express ACE2 and its cofactors. In this study, a total of 38 conjunctival samples from 38 patients, including 12 healthy conjunctivas, 12 melanomas, seven squamous cell carcinomas, and seven papilloma samples, were analyzed using high-throughput RNA sequencing to assess messenger RNA (mRNA) expression of the SARS-CoV-2 receptor ACE2 and its cofactors including TMPRSS2, ANPEP, DPP4, and ENPEP. ACE2 protein expression was assessed in eight healthy conjunctival samples using immunohistochemistry. Our results show that the SARS-CoV-2 receptor ACE2 is not substantially expressed in conjunctival samples on the mRNA (median: 0.0 transcripts per million [TPM], min: 0.0 TPM, max: 1.7 TPM) and protein levels. Similar results were obtained for the transcription of other auxiliary molecules. In conclusion, this study finds no evidence for a significant expression of ACE2 and its auxiliary mediators for cell entry in conjunctival samples, making conjunctival infection with SARS-CoV-2 via these mediators unlikely. Twit Text FOAVip Expression of the COVID-19 receptor ACE2 in the human conjunctiva ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32374427 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32374427 #FOAvip English Wikipedia <ref>{{Cite pmid|32374427}}</ref> Expression of the COVID-19 receptor ACE2 in the human conjunctiva #MMPMID32374427 Lange C; Wolf J; Auw-Haedrich C; Schlecht A; Boneva S; Lapp T; Horres R; Agostini H; Martin G; Reinhard T; Schlunck G J Med Virol 2020[Oct]; 92 (10): 2081-2086 PMID32374427show ga SARS-CoV-2 is assumed to use angiotensin-converting enzyme 2 (ACE2) and other auxiliary proteins for cell entry. Recent studies have described conjunctival congestion in 0.8% of patients with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and there has been speculation that SARS-CoV-2 can be transmitted through the conjunctiva. However, it is currently unclear whether conjunctival epithelial cells express ACE2 and its cofactors. In this study, a total of 38 conjunctival samples from 38 patients, including 12 healthy conjunctivas, 12 melanomas, seven squamous cell carcinomas, and seven papilloma samples, were analyzed using high-throughput RNA sequencing to assess messenger RNA (mRNA) expression of the SARS-CoV-2 receptor ACE2 and its cofactors including TMPRSS2, ANPEP, DPP4, and ENPEP. ACE2 protein expression was assessed in eight healthy conjunctival samples using immunohistochemistry. Our results show that the SARS-CoV-2 receptor ACE2 is not substantially expressed in conjunctival samples on the mRNA (median: 0.0 transcripts per million [TPM], min: 0.0 TPM, max: 1.7 TPM) and protein levels. Similar results were obtained for the transcription of other auxiliary molecules. In conclusion, this study finds no evidence for a significant expression of ACE2 and its auxiliary mediators for cell entry in conjunctival samples, making conjunctival infection with SARS-CoV-2 via these mediators unlikely. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Angiotensin-Converting Enzyme 2/genetics/metabolism[MESH] |COVID-19/complications/pathology/surgery/*virology[MESH] |Carcinoma, Squamous Cell/complications/pathology/surgery/*virology[MESH] |Case-Control Studies[MESH] |Conjunctiva/pathology/surgery[MESH] |Dipeptidyl Peptidase 4/genetics/metabolism[MESH] |Eye Neoplasms/complications/pathology/surgery/*virology[MESH] |Gene Expression[MESH] |Glutamyl Aminopeptidase/genetics/metabolism[MESH] |Humans[MESH] |Immunohistochemistry[MESH] |Male[MESH] |Melanoma/complications/pathology/surgery/*virology[MESH] |Middle Aged[MESH] |Papilloma/complications/pathology/surgery/*virology[MESH] |RNA, Messenger/genetics/metabolism[MESH] |Receptors, Virus/*genetics/metabolism[MESH] |SARS-CoV-2/genetics/metabolism[MESH]Expression of the COVID-19 receptor ACE2 in the human conjunctiva (epmc).pdf DeepDyve Pubget Overpricing